Abstract
Because DNA methyltransferase (DNMT) inhibitors like azacytidine and decitabine are known to be effective in the clinic for diseases like myelodysplastic syndromes that may result in part from transcriptional dysregulation due to epigenetic changes, there is interest in developing novel DNMT inhibitors that would be more effective and less toxic. The effects of one such agent, zebularine, which inhibits DNMT and cytidine deaminase, were assessed in two human breast cancer cell lines, MDA-MB-231 and MCF-7. Zebularine treatment inhibited cell growth in a dose and time dependent manner with an IC-50 of ~100 μM and 150 μM in MDA-MB-231 and MCF-7 cells, respectively, on 96 h exposure. This was associated with increased expression of p21, decreased expression of cyclin-D, and induction of S-phase arrest. At high doses zebularine induced changes in apoptotic proteins in a cell line specific manner manifested by alteration in caspase-3, Bax, Bcl2 and PARP cleavage. Like other DNMT inhibitors, zebularine decreased expression of DNMTs post-transcriptionally as well as expression of other epigenetic regulators like methyl CpG binding proteins and global acetyl H3 and H4 protein levels. Its capacity to reexpress epigenetically silenced genes in human breast cancer cells at low doses was confirmed by its ability to induce expression of estrogen and progesterone receptor mRNA in association with changes suggestive of active chromatin at the ER promoter as evidenced by ChIP. Finally, its effect in combination with other DNMT or HDAC inhibitors like decitabine or vorinostat was explored. The combination of 50 μM zebularine with decitabine or vorinostat significantly inhibited cell proliferation and colony formation in MDA-MB-231 cells compared with either drug alone. These findings suggest that zebularine is an effective DNMT inhibitor and demethylating agent in human breast cancer cell lines and potentiates the effects of other epigenetic therapeutics like decitabine and vorinostat.
Similar content being viewed by others
References
Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113. doi:10.1126/science.1145720
Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116. doi:10.1038/nrc1799
Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692. doi:10.1016/j.cell.2007.01.029
Momparler RL, Vesely J, Momparler LF, Rivard GE (1979) Synergistic action of 5-aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. Cancer Res 39:3822–3827
Santi DV, Norment A, Garrett CE (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81:6993–6997. doi:10.1073/pnas.81.22.6993
Constantinides PG, Taylor SM, Jones PA (1978) Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 66:57–71. doi:10.1016/0012-1606(78)90273-7
Gabbara S, Bhagwat AS (1995) The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307:87–92
Beisler JA (1978) Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem 21:204–208. doi:10.1021/jm00200a012
Constantinides PG, Jones PA, Gevers W (1977) Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267:364–366. doi:10.1038/267364a0
Marquez VE, Liu PS, Kelley JA, Driscoll JS, McCormack JJ (1980) Synthesis of 1, 3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase. J Med Chem 23:713–715. doi:10.1021/jm00181a001
Kim CH, Marquez VE, Mao DT, Haines DR, McCormack JJ (1986) Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem 29:1374–1380. doi:10.1021/jm00158a009
Laliberte J, Marquez VE, Momparler RL (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30:7–11. doi:10.1007/BF00686478
Marquez VE, Barchi JJ Jr, Kelley JA et al (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids 24:305–318. doi:10.1081/NCN-200059765
Hurd PJ, Whitmarsh AJ, Baldwin GS et al (1999) Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 286:389–401. doi:10.1006/jmbi.1998.2491
Cheng JC, Matsen CB, Gonzales FA et al (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399–409
Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF (2007) Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 35:263–273. doi:10.1016/j.exphem.2006.10.005
Rao SP, Rechsteiner MP, Berger C, Sigrist JA, Nadal D, Bernasconi M (2007) Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt’s lymphoma Akata cells. Mol Cancer 6:6
Cheng JC, Weisenberger DJ, Gonzales FA et al (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24:1270–1278. doi:10.1128/MCB.24.3.1270-1278.2004
Cheng JC, Yoo CB, Weisenberger DJ et al (2004) Preferential response of cancer cells to zebularine. Cancer Cell 6:151–158. doi:10.1016/j.ccr.2004.06.023
Agoston AT, Argani P, Yegnasubramanian S et al (2005) Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 280:18302–18310. doi:10.1074/jbc.M501675200
Hahm HA, Dunn VR, Butash KA et al (2001) Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin Cancer Res 7:391–399
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protocols 1:2315–2319. doi:10.1038/nprot.2006.339
Keen JC, Yan L, Mack KM et al (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81:177–186. doi:10.1023/A:1026146524737
Ferguson AT, Lapidus RG, Baylin SB, Davidson NE (1995) Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55:2279–2283
Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19:1740–1751. doi:10.1210/me.2004-0011
Margueron R, Licznar A, Lazennec G, Vignon F, Cavailles V (2003) Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 179:41–53. doi:10.1677/joe.0.1790041
Sheikh MS, Shao ZM, Chen JC, Li XS, Hussain A, Fontana JA (1994) Expression of estrogen receptors in estrogen receptor-negative human breast carcinoma cells: modulation of epidermal growth factor-receptor (EGF-R) and transforming growth factor alpha (TGF alpha) gene expression. J Cell Biochem 54:289–298. doi:10.1002/jcb.240540305
Barchi JJ, Musser S, Marquez VE (1992) The decomposition of 1-(beta-d-ribofuranosyl)-1, 2-dihydropyrimidin-2-one (zebularine) in alkali—mechanism and products. J Org Chem 57:536–541. doi:10.1021/jo00028a026
Yoo CB, Cheng JC, Jones PA (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32:910–912. doi:10.1042/BST0320910
Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R (2005) Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 70:121–133. doi:10.1016/j.bcp.2005.04.010
Pledgie-Tracy A, Sobolewski MD, Davidson NE (2007) Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 6:1013–1021. doi:10.1158/1535-7163.MCT-06-0494
Tamm I, Wagner M, Schmelz K (2005) Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol 84:47–53. doi:10.1007/s00277-005-0013-0
Neureiter D, Zopf S, Leu T et al (2007) Apoptosis, proliferation and differentiation patterns are influenced by zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 42:103–116. doi:10.1080/00365520600874198
Ye X, Franco AA, Santos H, Nelson DM, Kaufman PD, Adams PD (2003) Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol Cell 11:341–351. doi:10.1016/S1097-2765(03)00037-6
Nelson DM, Ye X, Hall C et al (2002) Coupling of DNA synthesis and histone synthesis in S phase independent of cyclin/cdk2 activity. Mol Cell Biol 22:7459–7472. doi:10.1128/MCB.22.21.7459-7472.2002
Milutinovic S, Zhuang Q, Niveleau A, Szyf M (2003) Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. J Biol Chem 278:14985–14995. doi:10.1074/jbc.M213219200
Flotho C, Claus R, Batz C et al. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. doi:10.1038/leu.2008.397
Rhee I, Bachman KE, Park BH et al (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552–556. doi:10.1038/416552a
Yang X, Ferguson AT, Nass SJ et al (2000) Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60:6890–6894
Yoo CB, Chuang JC, Byun HM et al (2008) Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res 1:233–240. doi:10.1158/1940-6207.CAPR-07-0008
Eliopoulos N, Cournoyer D, Momparler RL (1998) Drug resistance to 5-aza-2′-deoxycytidine, 2′, 2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 42:373–378. doi:10.1007/s002800050832
Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL (2005) Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 16:301–308. doi:10.1097/00001813-200503000-00009
Acknowledgments
This study was supported by grants from the National Institutes of Health (NIH CA 88843) and the Breast Cancer Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Billam, M., Sobolewski, M.D. & Davidson, N.E. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 120, 581–592 (2010). https://doi.org/10.1007/s10549-009-0420-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-009-0420-3